|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:fragrance
|
|
gptkbp:appointed_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:1996
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Gemzar
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:cisplatin
gptkb:carboplatin
gptkb:vaccine
radiation therapy
|
|
gptkbp:class
|
nucleoside analog
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe renal impairment
hypersensitivity to gemcitabine
|
|
gptkbp:developed_by
|
gptkb:United_States
|
|
gptkbp:discovered_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
1000 mg/m2
1250 mg/m2
1500 mg/m2
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
gemcitabine
|
|
gptkbp:ingredients
|
C9 H11 N3 O4
|
|
gptkbp:interacts_with
|
antibiotics
radiation therapy
antiviral medications
live vaccines
other chemotherapy agents
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
approximately 1 hour
|
|
gptkbp:marketed_as
|
gptkb:Gemzar
|
|
gptkbp:metabolism
|
deoxycytidine kinase
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
fever
vomiting
diarrhea
rash
thrombocytopenia
alopecia
neutropenia
stomatitis
low blood cell counts
|
|
gptkbp:targets
|
DNA synthesis
|
|
gptkbp:used_in
|
gptkb:healthcare_organization
bladder cancer
|
|
gptkbp:bfsParent
|
gptkb:ductal_adenocarcinoma
|
|
gptkbp:bfsLayer
|
4
|